leucovorin calcium / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 424 Diseases   807 Trials   807 Trials   14372 News 


«12...4849505152535455565758...235236»
  • ||||||||||  Characteristic and clinical outcome of localized gastric cancer; real-world data (Poster HALL LEVEL 0) -  May 6, 2023 - Abstract #ESMOGI2023ESMO_GI_577;    
    Our real-world data showed less favorable outcome than reported in clinical trials. Subgroup analysis comparing neoadjuvant FLOT vs FOLFOX/XELOX, pre-operative vs. peri-operative strategy and the value of added HIPEC and IORT will be presented in the meeting.
  • ||||||||||  5-fluorouracil / Generic mfg., irinotecan / Generic mfg.
    Chemotherapy treatment with mFOLFIRINOX in elderly patients with advanced pancreatic cancer (Poster HALL LEVEL 0) -  May 6, 2023 - Abstract #ESMOGI2023ESMO_GI_560;    
    Most patients required dose adjustments, and the median progression-free survival and overall survival were lower than clinical studies. Considering these results, this polychemotherapy scheme should be reserved for young or very selected patients.
  • ||||||||||  albumin-bound paclitaxel / Generic mfg.
    Comparison of second-line treatment after GEM/nab-PTX therapy for metastatic pancreatic cancer (Poster HALL LEVEL 0) -  May 6, 2023 - Abstract #ESMOGI2023ESMO_GI_497;    
    NAPOLI tended to be selected over mFFX for second-line treatment after GnP in older patients and in patients who did not respond to GnP. Howerver, there were also no statistically significant differences in clinical outcomes and adverse event rates in the matched pair cohort.
  • ||||||||||  5-fluorouracil / Generic mfg.
    Efficacy of the combined chemotherapy regimens in elderly patients with advanced pancreatic cancer (Poster HALL LEVEL 0) -  May 6, 2023 - Abstract #ESMOGI2023ESMO_GI_431;    
    We retrospectively analyzed the data of patients (pts)with metastatic pancreatic cancer aged 65 years and older who were treated with mFOLFIRINOX (oxaliplatin 85 mg/m2, irinotecan 150 mg/m2, leucovorin 400 mg/m2, 5FU 2400 mg/m2 for 46h), GemNab (gemcitabine 1000 mg/m2 1,8,15d, nab-paclitaxel 125mg/m2 1,8,15d) and monotherapy gemcitabine ((Gem), 1000mg/m2 1,8,15d) in our center... mFOLFIRINOX and GemNab regimens are active in elderly patients with advanced pancreatic cancer and should be considered as a standard of care.
  • ||||||||||  Kaitanni (cadonilimab) / Akesobio
    Efficacy and safety of cadonilimab combined with FLOT regimen as a neoadjuvant therapy for locally advanced gastric/gastroesophageal junction adenocarcinoma: A prospective, multicenter, open-label, single-arm phase II study (Poster HALL LEVEL 0) -  May 6, 2023 - Abstract #ESMOGI2023ESMO_GI_401;    
    NEONIPIGA trial proved that nivolumab and ipilimumab-based NAT in patients with dMMR/MSI-H resectable G/GEJ adenocarcinoma is feasible, and achieved a significant (pathological complete response) pCR rate over programmed cell death-1 (PD-1) antibody alone...Participants received 4 preoperative cycles of cadonilimab (10mg/kg, IV, q3w) plus FLOT (docetaxel 50mg/m2, oxaliplatin 85mg/m2, 5-FU 2600mg/m2, leucovorin 200mg/m2, IV, q3w) therapy, following a radical gastrectomy and 4 cycles of FLOT adjuvant chemotherapy every 3 weeks...Tumor Secondary endpoints include major pathological response (MPR) rate, objective response rate (ORR), disease control rate (DCR), incidence of TRAEs and irAEs during preoperative and postoperative treatment period, R0 resection rate, postoperative complications and overall survival (OS) and progression-free survival (PFS).Clinical trial identification: Chictr.org.cn, ChiCTR2200066893.Editorial acknowledgement: This study was sponsored by Akeso Biopharma, Inc. Medical writing support/editorial support, under the direction of the authors, was provided by Yongkang Zhang and was funded by Akeso Biopharma, Inc.Legal entity responsible for the study: Akeso Biopharma, Inc.
  • ||||||||||  Total neoadjuvant therapy for locally advanced rectal cancer: A UK cohort (Poster HALL LEVEL 0) -  May 6, 2023 - Abstract #ESMOGI2023ESMO_GI_384;    
    In patients who underwent surgery, a high rate of R0 resection and complete pathologic response was seen despite majority of patients having a dose reduction of chemotherapy. Early outcomes in this high-risk rectal cancer cohort are similar to those reported in recent trials.
  • ||||||||||  Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer
    Retrospective analysis of management of BRAF V600E mutated colorectal cancer in a single institution (Poster HALL LEVEL 0) -  May 6, 2023 - Abstract #ESMOGI2023ESMO_GI_383;    
    Our study emphasizes the poor prognosis of BRAF V600E-mutated metastasic colorrectal cancer, In our population, similar as the one in the BEACON study, the combination of encorafenib-cetuximab stands out as a well-tolerated option in second line, with a PFS of 9,9 months. Of note, in our experience encorafenib-cetuximab could also be a remarkable option in third-line setting, with a PFS of 10,4 months.
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
    Evaluation of predictive factors of toxicity of chemotherapy with FOLFIRINOX in patients treated for pancreatic adenocarcinoma (Poster HALL LEVEL 0) -  May 6, 2023 - Abstract #ESMOGI2023ESMO_GI_376;    
    In our retrospective cohort of pancreatic cancers treated with FOLFIRINOX, toxicities requiring dose reduction and/or hospitalization were frequent (48%) and their occurrence correlated with the presence of low muscle mass and/or high NLR. This study requires confirmation in a larger series but suggests that the assessment of muscle mass and NLR ratio could limit the toxicities of FOLFIRINOX chemotherapy.
  • ||||||||||  Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, Cyramza (ramucirumab) / Eli Lilly
    The screening and consensus based on practices and evidence (SCOPE) survey  (Poster HALL LEVEL 0) -  May 6, 2023 - Abstract #ESMOGI2023ESMO_GI_372;    
    PD-L1 testing may increase now, due to availability of immune checkpoint inhibitors in 1L. The main 3L treatment goals were to preserve QOL, prolong survival, and relieve symptoms, which aligned with patients' concerns about deterioration of daily activities.
  • ||||||||||  5-fluorouracil / Generic mfg.
    Multisite intratumoral chemotherapy improves treatment outcome in a murine model with pancreatic ductal adenocarcinoma (Poster HALL LEVEL 0) -  May 6, 2023 - Abstract #ESMOGI2023ESMO_GI_322;    
    These positive preclinical efficacy studies support our hypothesis on the importance of greater dispersion of drugs in the dense stroma of the pancreatic tumor. Using the innovative OnePass Medical EUS multi-needle device for direct multisite delivery into the tumor of various therapeutic agents has the potential of improving treatment results for patients with LAPC.
  • ||||||||||  Overcoming chemoresistance in patients with metastatic colorectal cancer using hepatic arterial infusion (Poster HALL LEVEL 0) -  May 6, 2023 - Abstract #ESMOGI2023ESMO_GI_316;    
    All of them had progressed on >2 previous lines of systemic therapy with fluoropyrimidines, oxaliplatin and irinotecan. Hepatic artery infusion with oxaliplatine and 5-fluorouracil, combined with intravenous leucovorin, can be considered as an option for heavily-pretreated and chemoresistant patients with liver metastases of colorectal cancer, as it is well-tolerated and demonstrates good response rates and tumor control rates.
  • ||||||||||  5-fluorouracil / Generic mfg.
    The role of preoperative immune-chemotherapy in locally advanced resectable gastric cancer with microsatellite instability (Poster HALL LEVEL 0) -  May 6, 2023 - Abstract #ESMOGI2023ESMO_GI_278;    
    Hepatic artery infusion with oxaliplatine and 5-fluorouracil, combined with intravenous leucovorin, can be considered as an option for heavily-pretreated and chemoresistant patients with liver metastases of colorectal cancer, as it is well-tolerated and demonstrates good response rates and tumor control rates. Our study shows worse survival results among patients with MSI-H gastric cancer in comparison with patients with MSS-tumors undergoing modern chemotherapy (FLOT/FOLFIRINOX), but a combination of nivolumab+chemotherapy in patients with MSI-H gastric cancer shows a high rate of pathological response of any grade (100% of cases, TRG-1 to TRG-4) and pathological complete response (60% of cases, TRG-1).
  • ||||||||||  Locally advanced gastric cancer under FLOT  (Poster HALL LEVEL 0) -  May 6, 2023 - Abstract #ESMOGI2023ESMO_GI_273;    
    Despite these data, DFS seems to be improved in patients which are treated with curative intent, suggesting that the immune system might play a role. With almost one third of the patients in this cohort having dMMR, parallel to the emerging data regarding neoadjuvant immunotherapy in this setting, a more targeted patient selection and tailored treatment is currently an unmet need.
  • ||||||||||  Onivyde (nanoliposomal irinotecan) / Servier, Ipsen, Takeda
    Is there room for nal-IRI in biliary tract cancer? (Poster HALL LEVEL 0) -  May 6, 2023 - Abstract #ESMOGI2023ESMO_GI_271;    
    However, the control arm of the pivotal arm was the active symptom control alone. Furthermore, not all patients are eligible to this therapy and not all benefit from it.
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., capecitabine / Generic mfg.
    Circulating tumor DNA could have impact on risk assessment and personalizing adjuvant therapy in localized colon cancer (Poster HALL LEVEL 0) -  May 6, 2023 - Abstract #ESMOGI2023ESMO_GI_253;    
    Low risk stage III with high ctDNA observed high recurrence rate and poor survival so, total six months of adjuvant treatment could be studied for this group. High risk stage III with combined (MSI-H and high ctDNA) showed poor behavior and poor survival so, introduction of immunotherapy could be tested in future in early adjuvant and maintenance setting.
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
    Transcriptome-based classification to predict FOLFIRINOX response in a real-world metastatic pancreatic cancer cohort (POSTER HALL LEVEL 0) -  May 6, 2023 - Abstract #ESMOGI2023ESMO_GI_228;    
    Our results indicate that the predictive value of transcriptomic subtyping can be translated into a large Dutch real-world cohort, consisting of academic and regional hospitals. Given that only half of the prospectively included patients yielded evaluable biopsies for RNA-sequencing, probably surrogate biomarkers for transcriptome-based subtyping, such as immunohistochemistry, will be more feasible in clinical practice to predict FOLFIRINOX response.
  • ||||||||||  Lynparza (olaparib) / Merck (MSD), AstraZeneca
    Organoids as tools for functional precision oncology in advanced pancreatic cancer (POSTER HALL LEVEL 0) -  May 6, 2023 - Abstract #ESMOGI2023ESMO_GI_226;    
    P1
    We could identify in a clinically relevant turnaround time at least one putative hit on the chemogram in 90% of cases, and in 87% of cases hits were not SOC. These results warrant to be confirmed in a prospective randomized trial to address the efficacy of PDO-based functional precision oncology for the management of PDAC.
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
    Predictive values of blood-based RNA signature for the FOLFIRINOX/FOLFOX response in advanced pancreatic cancer (Auditorium B, Level 0) -  May 6, 2023 - Abstract #ESMOGI2023ESMO_GI_194;    
    P=N/A
    The F/FX demonstrates the potential of a blood-based RNA signature as a minimally-invasive alternative to improve patient survival and implement personalized therapy in PDAC for patients treated with a FOLFIRINOX/FOLFOX regimen as first-line treatment. While these data show promise, they should be confirmed in a prospective trial, distinguishing patients with non resectable locally advanced and those with metastatic tumors.